npj Breast Cancer · 2015 · 61 citations · 23 references
MedicineCancer BiologyOncologyBreast OncologyMetastasisTumor ProgressionCancer ProgressionLymphatic SpreadMalignant NeoplasmsMetastatic Breast CancerMetastatic CascadeMetastatic DisseminationBreast Cancer ProgressionDistant Metastatic SpreadMetastasis ModelsMetastasis PredictionMetastatic Dissemination RoutesMetastatic EvolutionMetastatic Progression ModelingTumor Progression Dynamics
BACKGROUND: Cancer cell migration patterns are critical for understanding metastases and clinical evolution. Breast cancer spreads from one organ system to another via hematogenous and lymphatic routes. Although patterns of spread may superficially seem random and unpredictable, we explored the possibility that this is not the case. AIMS: Develop a Markov based model of breast cancer progression that has predictive capability. METHODS: On the basis of a longitudinal data set of 446 breast cancer patients, we created a Markov chain model of metastasis that describes the probabilities of metastasis occurring at a given anatomic site together with the probability of spread to additional sites. Progression is modeled as a random walk on a directed graph, where nodes represent anatomical sites where tumors can develop. RESULTS: We quantify how survival depends on the location of the first metastatic site for different patient subcategories. In addition, we classify metastatic sites as "sponges" or "spreaders" with implications regarding anatomical pathway prediction and long-term survival. As metastatic tumors to the bone (main spreader) are most prominent, we focus in more detail on differences between groups of patients who form subsequent metastases to the lung as compared with the liver. CONCLUSIONS: We have found that spatiotemporal patterns of metastatic spread in breast cancer are neither random nor unpredictable. Furthermore, the novel concept of classifying organ sites as sponges or spreaders may motivate experiments seeking a biological basis for these phenomena and allow us to quantify the potential consequences of therapeutic targeting of sites in the oligometastatic setting and shed light on organotropic aspects of the disease.
23
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Gene expression profiling predicts clinical outcome of breast cancer
Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Trastuzumab-Induced Hepatotoxicity: A Case Report
D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin · Breast Care · 2013 · 4.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Genes that mediate breast cancer metastasis to lung
Andy J. Minn, Gaorav P. Gupta, Peter M. Siegel et al. · Nature · 2005 · 3K citations · Full text